Document is current

Article History

Received: 19 July 2024

Revised: 6 December 2024

Accepted: 4 February 2025

First Online: 19 March 2025

Competing interests

: BDS reports consulting/advisory role for Adaptive Biotechnologies, Amgen, Autolus, BeiGene, Bristol Myers Squibb, Century Therapeutics, Deciphera, Jazz, Kite, a Gilead Company, Lilly, Novartis, Precision Biosciences, Pfizer, and Takeda; research funding from Jazz Pharmaceuticals, Kite, and Servier; and other relationship with PeproMene Bio. RDC reports employment with and stock or other ownership in Seagen (immediate family member); honoraria from Amgen, Jazz, Kite, a Gilead Company, and Pfizer; consultancy/advisory role for Amgen and Kite; research funding from Amgen, Incyte, Kite, Merck, Pfizer, Servier, and Vanda; travel support from Kite; and other relationship with Autolus (independent review committee), and PeproMene Bio (DSMB). JHP reports consulting/advisory role for AstraZeneca, Kite, a Gilead Company, and Novartis; and research funding from Amgen, Genentech, and Juno. RH reports honoraria from ADC Therapeutics, Bristol Myers Squibb, Celgene, Gilead Sciences, Janssen, Kite, a Gilead Company, MSD, and Novartis; and consulting/advisory role for Kite and Gilead Sciences. ACL reports consulting/advisory role for AbbVie, Actinium, Bristol Myers Squibb, Pfizer, and Takeda; research funding from Amgen, Astellas, Autolus, Kadmon, Kite, a Gilead Company, Pharmacyclics, and Talaris; and other relationship with DSMB: Servier. NB reports honoraria and consulting/advisory role for Amgen, Kite, a Gilead Company, and Novartis; and research funding and expert testimony for Amgen. TL reports honoraria from Amgen, Incyte, Kite, a Gilead Company, and Servier; and consulting/advisory role for Amgen, Incyte, and Servier. MiRB reports honoraria from ADC Therapeutics, Bristol Myers Squibb, Incyte, and Sanofi; consulting/advisory role for Bristol Myers Squibb, Kite, a Gilead Company, Novartis, and Sana Bio; and speakers’ bureau participation for ADC Therapeutics, Bristol Myers Squibb, Incyte, and Sanofi. MST reports consulting/advisory role for AstraZeneca, Bristol Myers Squibb, Genmab, Kite, a Gilead Company, and Roche; research funding from Kite, Regeneron, Roche, and Takeda; and travel support from Janssen and Kite. KMO has no relevant financial relationships to disclose. DT reports consulting/advisory role for and research funding from Bristol Myers Squibb. MLA reports consulting/advisory role for Kite, a Gilead Company and Syndax Pharmaceuticals, Inc.; and research funding from Kite (Institutional PI). YL reports consulting/advisory role for Janssen, Sanofi, NexImmune, Caribou, BMS, Pfizer, Regeneron; research funding from BMS and Jansen. MRB reports research funding from AbbVie, Ascentage, Kite, a Gilead Company, Kura, and Takeda. GJS reports honoraria and research funding from and speakers’ bureau participation for Kite, a Gilead Company. MS reports consulting/advisory role for Amgen, Celgene/Bristol Myers Squibb, Gilead Sciences, Janssen, and Novartis; speakers’ bureau participation for Celgene/Bristol Myers Squibb, Gilead Sciences, Janssen, and Novartis; research funding from Amgen, Gilead Sciences, Miltenyi Biotec, MorphoSys, Roche, and Seagen; and travel support from Takeda. MA reports honoraria from and consulting/advisory role for Celgene; speakers’ bureau participation for AbbVie, Bristol Myers Squibb, Celgene, and Kite, a Gilead Company. MCM reports consulting or advisory role for Bristol Myers Squibb, CDR-life, GSK, and Janssen/Cilag (institution); speakers’ bureau participation for WebMD, Siemens, and Pfizer (institution); and research funding from BeiGene (institution). WGW reports consulting/advisory role for Genzyme and Sanofi; and research funding from AbbVie, Acerta, Cyclacel, Genentech, Gilead Sciences, GSK, Janssen, Juno, Karyopharm, Loxo Oncology, miRagen, Novartis, Oncternal, Pharmacyclics, Sunesis, and Xencor. DJD reports consulting or advisory role for Agios, Amgen, Autolus, Blueprint, Forty-Seven, Gilead Sciences, Incyte, Jazz, Novartis, Pfizer, Shire, and Takeda; and research funding from AbbVie, GlycoMimetics, Novartis, and Blueprint Pharmaceuticals. PS reports honoraria from and consulting or advisory role for MorphoSys and CRISPR Therapeutics; and research funding from Amgen, Gamida Cell, Pfizer, Karyopharm, Gilead Sciences, Incyte, Seagen, and Cellectar. DJ reports research funding from Jazz Pharmaceuticals and Pfizer. DM has no relevant financial relationships to disclose. SA reports employment with and stock or other ownership in Kite, a Gilead Company. LZ reports employment with Kite, a Gilead Company; and stock or other ownership in AbbVie RSU. TH reports employment with, stock, or other ownership in Kite, a Gilead Company. RDK reports employment with, stock or other ownership in, and travel support from Kite, a Gilead Company. AG reports honoraria from Kite, a Gilead Company; consulting/advisory role for Amgen, Atara, Bristol Myers Squibb, CRISPR Therapeutics, Kite, and Wugen Inc.; research funding from Amgen, Genentech, and Kite. OOO reports honoraria from Gilead Sciences and Pfizer; consulting/advisory role for AbbVie, ADC, Cargo, Caribou Biosciences, Epizyme, Gilead Sciences, Kite, a Gilead Company, Nektar, Novartis, Pfizer, and TGR; speakers’ bureau participation for ADC; and research funding from Allogene, Daiichi Sankyo, Kite, and Pfizer.